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Abstract
Background: During the year following the birth of a child, 40% of women are estimated to have an unmet need
for contraception. The copper IUD provides safe, effective, convenient, and long-term contraceptive protection that
does not interfere with breastfeeding during the postpartum period. Postpartum IUD (PPIUD) insertion should be
performed by a trained provider in the early postpartum period to reduce expulsion rates and complications, but
these services are not widely available. The International Federation of Obstetricians and Gynecologists (FIGO) will
implement an intervention that aims to institutionalize PPIUD training as a regular part of the OB/GYN training
program and to integrate it as part of the standard practice at the time of delivery in intervention hospitals.
Methods: This trial uses a cluster-randomized stepped wedge design to assess the causal effect of the FIGO
intervention on the uptake and continued use of PPIUD and of the effect on subsequent pregnancy and birth.
This trial also seeks to measure institutionalization of PPIUD services in study hospitals and diffusion of these
services to other providers and health facilities. This study will also include a nested mixed-methods performance
evaluation to describe intervention implementation.
Discussion: This study will provide critical evidence on the causal effects of hospital-based PPIUD provision on
contraceptive choices and reproductive health outcomes, as well as on the feasibility, acceptability and longer run
institutional impacts in three low- and middle-income countries.
Trial registration: Trial registered on March 11, 2016 with ClinicalTrials.gov, NCT02718222.
Keywords: Postpartum contraception, IUD, Impact evaluation
Background
Postpartum access to insertion of an intrauterine device
(IUD) is critical for meeting women’s need for long-acting
but reversible contraceptive protection. The IUD is safe,
effective, long-acting, reversible, and convenient, espe-
cially when inserted in the immediate postpartum period
[1]. The postpartum IUD (PPIUD) does not interfere with
breastfeeding, is safe for use by all women, including HIV-
positive women, is associated with less discomfort and
fewer side effects than interval IUD insertion, and allows
women to obtain safe, long-acting (up to 12 years), highly
effective yet reversible contraceptive protection that can
be made readily available to women delivering in health
facilities. In countries where women do not return for
postnatal follow-up visits because of cost, distance, or
health system challenges PPIUD offers a convenient and
cost-effective postpartum contraceptive option.
Despite these well-established benefits of PPIUD, its up-
take continues to be low. During the year following the
birth of a child, 40% of women are estimated to have an un-
met need for contraception [2]. Fewer than 50% of women
in 30 of the 43 countries with recent Demographic and
Health Surveys (DHS) used any method of contraception
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during 9-11 months postpartum, and in 12 of these
countries the use was below 20% [3]. The copper-bearing
intrauterine device (copper IUD) is a safe and effective
method that can be used immediately after delivery [4]; yet,
only in three of the 43 counties (Egypt, Kyrgyz Republic
and Tajikistan), were 20% or more of postpartum users of
contraception relying on this method [3].
A number of studies and systematic reviews have evalu-
ated the safety, efficacy and acceptability of immediate
postpartum insertion of IUDs (within 10 min of delivery of
the placenta) compared to delayed postpartum insertion
(more than 10 min to 48 or 72 h following delivery) or
interval insertion (after four or six weeks following
delivery). Two systematic reviews of the evidence con-
firmed the safety and effectiveness of postpartum IUD
insertions [1, 5]. Fifteen studies included in the first review
showed that immediate IUD insertion was safe when
compared with delayed postpartum and interval insertion.
Immediate postpartum insertion had lower expulsion rates
when compared to delayed postpartum insertion, but had
higher expulsion rates when compared to interval inser-
tion. The authors also noted that immediate insertion
following Caesarean delivery demonstrated lower expulsion
rates than immediate insertion following vaginal delivery.
The review by Grimes et al. (2010) covered nine random-
ized controlled trials and showed higher expulsion rates of
immediate postpartum IUD insertion than interval inser-
tion [5]. Eroğlu et al. (2006) is the only study to compare
immediate postpartum insertion and delayed postpartum
IUD insertions with interval insertion [6]. Among 268
women using TCu 380A IUDs in one hospital in Ankara,
Turkey, expulsions within a year after insertion were the
highest in the group that had delayed IUD insertion (70%)
as compared to immediate postpartum insertion (37%) and
to those receiving interval insertion (7%; p < 0.003) [6].
Several studies reported acceptability of postpartum IUDs
in diverse settings when information and counselling on
postpartum contraceptive methods was provided to women
[7–9]. To expand the use of PPIUD, high-quality counsel-
ling during the antenatal period and training of physicians
and midwives is critical [10]. However, in countries where
antenatal care rates are low or antenatal care does not
include counseling on postpartum contraception due to
lack of provider time or training, women may not receive
information on PPIUD before coming to the hospital for
delivery. Despite higher expulsion rates, providers may
counsel these women after delivery and offer PPIUD inser-
tion after the 10-min window for immediate PPIUD inser-
tion has passed. Expulsions will be lower if: (a) the IUD is
inserted within 10 min after delivery of the placenta; (b)
placement is sufficiently high in the uterine fundus; and (c)
insertion is done by a specially trained provider [1, 11, 12].
This trial is an impact evaluation of an intervention im-
plemented by the International Federation of Gynaecology
and Obstetrics (FIGO) that seeks to institutionalize PPIUD
services, both immediate and delayed insertion, as a routine
part of antenatal counselling and delivery room services in
Sri Lanka, Nepal and Tanzania.
Methods
Aims
This trial aims to determine the causal effect of the inter-
vention on the uptake and subsequent continued use of
PPIUD. The extent to which the intervention leads to the
institutionalization of PPIUD services in the hospitals dur-
ing and after the FIGO intervention, and to what extent
the services diffuse to other hospitals or providers will also
be assessed. In addition, the coverage and quality of post-
partum contraceptive counselling and service provision
will be measured, including women and providers’ satisfac-
tion with these services.
Specifically, the study aims to determine:
1) The coverage and quality of counselling for
postpartum family planning
2) The causal effect of the intervention on effective
access to postpartum IUD during and 12 months
after the end of the intervention period
3) The causal effect of the intervention on utilization of
postpartum IUD during and 12 months after the
end of the intervention period
4) The causal effect of the intervention on postpartum
contraceptive use and method mix
5) The quality of the IUD services provided during the
intervention period measured by expulsions,
complications, and discontinuation
6) The causal effect of the intervention on postpartum
reproductive behaviour and outcomes, including
pregnancy, fertility, and abortion
7) The satisfaction of providers with the training they
received, provision of services and their perspectives
on scaling up PPIUD services
8) The satisfaction of women with postpartum IUD
services and reasons for non-use and
discontinuation
9) The institutionalization and diffusion of the PPIUD
intervention
10)Health system and cultural facilitators and barriers to
the successful implementation, institutionalization,
and diffusion of postpartum IUD services
Ethics approval
Ethical approval as exempt was granted by the Harvard
T.H. Chan School of Public Health Office of Human
Research Administration as Harvard will only receive
de-identified datasets, and each country received ethical
approval from the appropriate national Institutional
Review Board (IRB). More specifically, the study received
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approval from the Ethics Review Committee at the Faculty
of Medicine at the University of Colombo in Sri Lanka,
the Nepal Health Research Council, and the National In-
stitute for Medical Research in Tanzania. Protocol amend-
ments were submitted for review and approval to each
country’s IRB whenever changes to the protocol, consent
forms, or questionnaires were made.
Randomization of hospitals
Because of the potential benefit of the intervention to all
women, a cluster-randomized stepped wedge design was
considered most appropriate for the study. Six hospitals
were selected in each country to provide national geo-
graphic coverage, and were randomized into two groups of
three. Facilities were matched by number of deliveries per
year, and one was randomly selected from each pair to be
assigned to Group 1 while the other was assigned to Group
2. Using Stata software, researchers at Harvard T.H. Chan
School of Public Health generated a random number that
was assigned to each hospital. The hospital with the higher
random number in the pair was assigned to Group 2, while
the hospital with the lower random number in the pair
was assigned to Group 1. A full list of study facilities is
available upon request. The study enrolment period for
both groups will be 12 months in Tanzania and 18 months
in Nepal and Sri Lanka. In Group 1, the baseline standard
of care (SOC) period will be three months and the PPIUD
intervention period will be nine months in Tanzania and
fifteen months in Nepal and Sri Lanka. In Group 2, the
baseline (SOC) period will be nine months and the PPIUD
intervention period three months in Tanzania and nine
months in Nepal and Sri Lanka. We can represent this
design for each group as follows:
Due to the randomized nature, the causal effect of the
intervention on the outcomes of interest can be estimated.
In months 4-9, a randomized contrast can be made that
will be controlled for any secular trends in outcomes. In
addition, before-after contrasts will be made within hospi-
tals controlled for all time-invariant differences in event
rates between hospitals. The reference population for the
study will be all women in the catchment area delivering
in each hospital within a period of 12 months from the
start of the study in Tanzania and within a period of 18
months in Nepal and Sri Lanka.
Participant selection criteria
Women
Selection criteria for the study vary by country based on
local regulations and the structure of the health system. In
Sri Lanka, women will be eligible to participate in the
study (inclusion criterion) if they deliver in one of the six
study hospitals during the 18-month enrolment period,
unless they normally reside outside of Sri Lanka. The
study will interview women at up to four time points:
baseline (in the hospital soon after delivery), 4-8 weeks
postpartum for those who have PPIUD inserted, 9 months
postpartum, and 18 months postpartum. In Sri Lanka, pri-
mary care services such as child immunizations are not
available in the study hospitals, and the 9-month and 18-
month surveys will be completed in satellite clinics affili-
ated with the study hospitals. There can be many satellite
clinics affiliated with each hospital, and three to four will
be selected based on geographic representation and the
percentage of women delivering in the study hospitals
who may receive postnatal care at the selected satellite
clinics. Women enrolled at baseline will be eligible to
complete the 9-month and 18-month surveys if they live
in the catchment for one of the selected satellite clinics.
In Nepal, women will be eligible to participate in the
study if they deliver in one of the six study hospitals dur-
ing the 18-month enrolment period, unless they normally
reside outside of the country. As in Sri Lanka, the study
will interview women at up to four time points: baseline
(in the hospital soon after delivery), 4-8 weeks postpartum
for those who have PPIUD inserted, 9 months postpar-
tum, and 18 months postpartum. In Nepal, because of the
mountainous terrain and long travel times to reach re-
mote areas, only women who live within 24 h of the study
hospital will be eligible for the 9-month and 18-month fol-
low up. Due to the high delivery caseload in the six hospi-
tals selected in Nepal, a 55% sample of women enrolled at
baseline who live within 24 h of the study hospital will be
randomly selected to complete the two long-term follow
up interviews at 9 months and 18 months postpartum.
The long-term follow-up interviews will be conducted in
the hospital when possible, but for participants unable to
return to the hospital, enumerators will conduct inter-
views at the participant’s home or another location of the
participant’s choosing.
In Tanzania, women will be eligible to participate in the
study if they are age 18 or older and deliver in one of the
study hospitals during the 12-month enrolment period, un-
less they normally reside outside of Tanzania. As in Sri
Lanka, primary care services in Tanzania are not available
in the study hospitals, and the 9-month and 18-month sur-
veys will be completed in satellite clinics affiliated with the
study hospitals. Three to four clinics will be selected based
on geographic representation and the percentage of
women delivering in the study hospitals who may receive
Time (months) 1-3 4-9 10-12 (Tanzania)
10-18 (Nepal and Sri Lanka)
Group 1 (Hospitals 1-3) O X X
Group 2 (Hospitals 4-6) O O X
where X = PPIUD intervention and O= control (standard of care provided)
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postnatal care at the selected satellite clinics. In Tanzania,
selection for the follow-up surveys is not dependent on en-
rolment at baseline. Data collectors will be posted at the
selected satellite clinics, and women may be enrolled in the
study at the time of the 9-month or 18-month survey when
they visit the satellite clinics for child immunization
services if they meet the eligibility criteria for the study
(delivered in one of the six intervention hospitals during
the 12-month enrolment period, normally reside in
Tanzania, and are age 18 or older).
Providers
The provider sample includes all medical personnel who
could potentially provide PPIUD who are working in the
study hospitals during the 15-month intervention period,
along with those who are working in the hospitals 12
months after the end of the study period. In Sri Lanka, only
doctors are eligible to provide PPIUD services, and all eli-
gible doctors were included. In Nepal and Tanzania, a ran-
dom sample of providers was selected to participate in the
Provider Survey. A full list of doctors and nurses eligible to
provide PPIUD services was obtained, and stratified random
sampling was used to select an equal number of providers
from each cadre in each facility to complete the survey.
The intervention
The International Federation of Gynaecology and Obstet-
rics (FIGO) has designed and will implement, through its
nationally-affiliated Associations of Gynaecologists and
Obstetricians, an intervention program on PPIUD ser-
vices. As part of this Program, FIGO is responsible for the
development and production of informational materials,
training providers in counselling and in the provision of
PPIUDs, improving facilities, ensuring good quality of ser-
vice, and monitoring the program. Each component of the
intervention is described in detail below.
Coordination with ministries of health
In order to introduce the provision of PPIUD services in a
manner that is sustainable and achieves integration as part of
the standard training and delivery practice, FIGO and their
national affiliates will work closely with each country’s Minis-
try of Health to ensure adherence to national guidelines and
to ensure quality of training and monitoring activities.
Training of providers
The facilities chosen in each country are primarily teach-
ing hospitals who wish to include PPIUD as part of the
regular OB/GYN training program and to integrate it as
part of the standard delivery practice in these institutions.
Health professionals will be trained through a combin-
ation of specific classroom-based training sessions and on
the job training and mentoring, with new staff undertak-
ing training as they rotate to the facilities.
Courses for approximately 12 master trainers, two
from each participating hospital, will be organized. The
training will include lectures, videos, web-based learning
material, master classes and practical exercises on man-
nequins. Supervised IUD insertions and counselling ses-
sions on patients will subsequently take place in order to
establish competency.
These master trainers, who will be respected health
care professionals with experience in implementing
evidence-based clinical practices, will subsequently train
the resident obstetrician/gynaecologists, the health facil-
ities’ delivery team, the facilities’ antenatal team, and the
community midwives in PPIUD related service delivery.
All health providers involved in the project will be
trained on counselling women on the benefits of adopt-
ing a postpartum contraceptive method for birth-spacing
and maternal and infant health.
Training of community intermediaries
Community-based intermediaries, including midwives,
skilled birth attendants and community health workers,
are often the first point of contact for pregnant women
in semi-urban areas. In an effort to increase the accept-
ance of PPIUD services, this intervention will orient
community intermediaries linked with each hospital on
postpartum contraception and PPIUD to enable them to
integrate postpartum family planning content into their
regular community-level activities, including counselling
of pregnant women.
PPIUD service delivery
Women presenting at selected hospitals and associated
clinics will receive information on postpartum contra-
ception and the availability of PPIUD services during
antenatal care and after delivery. The intervention will
support printing of local government-approved leaflets
on postpartum contraception and PPIUD to be used
during counselling. In addition, the intervention will
supply at least one TV for each hospital, and a video on
postpartum contraception and PPIUD will be played in
the local language. Informed consent for PPIUD will be
obtained at the time of counselling and case notes
marked for easy identification. Consent for PPIUD will
be taken again immediately prior to PPIUD insertion
and noted in the maternity records. Those women who
have an IUD fitted will be encouraged to attend a
follow-up visit with her midwife or the hospital/associ-
ated satellite clinic. Where possible, follow-up will be
combined with the child’s 4-8-week immunization visit.
Each selected facility has a facility coordinator who
will be responsible for working with the National Project
Coordinator to have an effective stock management sys-
tem in place and for ensuring that there are sufficient
supplies of IUDs, proper inserters such as long curved
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Kelly’s forceps, clinical notes, patient information litera-
ture and consent forms.
Monitoring and mentoring
In order to track progress against the intervention’s ob-
jectives and to improve provider performance, FIGO
and the in-country FIGO affiliates will regularly monitor
service delivery data to provide support, if needed, to
improve the performance of providers at the participat-
ing hospitals.
Outcome measures
Study outcomes will be assessed using a variety of research
instruments. Quantitative interviewer-administered surveys
will be conducted with women at up to four time points:
1. Baseline (in hospital after delivery)
2. 4–8 weeks after delivery among women who
accepted PPIUD
a. Providers ask women to get a PPIUD check-up at
4-6 weeks postpartum, and these data can be
collected between 2-12 weeks after delivery
3. 9 months after delivery
a. Can be collected 8-14 months after delivery
4. 18 months after delivery
a. Can be collected 15-21 months after delivery
Quantitative interviewer-administered surveys will also
be conducted with providers at three time points:
1. Baseline, prior to implementation of FIGO
intervention
2. 6 months after implementation begins
3. 12 months after implementation ends
A facility survey using a checklist will also be completed
before the intervention, 6 months after the intervention
has begun, and 12 months after the end of intervention
implementation to examine the extent to which PPIUD
counselling and services have been institutionalized.
Primary and secondary outcomes are listed in Additional
file 1, and key outcomes of interest are described in greater
detail below:
1. Uptake of PPIUD
To ascertain what percentage of women delivering
in study hospitals take up PPIUD, participants will
be interviewed after delivery, before they are
discharged from the hospital
2. Receipt of PPIUD counseling before or after delivery
To ascertain what percentage of women delivering
in study hospitals receive counseling on PPIUD,
participants will be interviewed after delivery,
before they are discharged from the hospital. They
will also be asked questions to assess the quality of
the counseling.
3. PPIUD expulsion rate and complication rate at 4-8
weeks postpartum
Participants who have not deliberately removed
the PPIUD will be examined by providers at 4-8
weeks postpartum, and providers will report
whether the PPIUD was expelled or complications
occurred.
4. Modern contraceptive use at 9 months postpartum
Participants will be interviewed at 9 months and
asked whether they are using a modern method of
contraception, defined as pill, implant, injectable,
IUD, condom, or sterilization for the purposes of
this study.
5. Modern contraceptive use at 18 months postpartum
Participants will be interviewed at 18 months and
asked whether they are using a modern method of
contraception.
6. Pregnancy rate at 18 months postpartum
Participants will be interviewed at 18 months and
asked whether they are currently pregnant or have
had a pregnancy that was terminated.
7. Sustainability: Percentage of trained providers who
are still providing PPIUD services 12 months after
the end of implementation
Providers originally trained under the FIGO
intervention will be interviewed at 12 months after
intervention implementation ends to assess
whether PPIUD services have continued after
intervention support ends, suggesting
institutionalization of services in the facility.
8. Sustainability: Percentage of trained providers
providing PPIUD services in new facilities (after
transfer) 12 months after the end of implementation
It is expected that some providers originally
trained under the FIGO intervention will be
transferred to new facilities as is the practice in all
three study countries. Providers originally trained
under the FIGO intervention and transferred to
new facilities will be interviewed 12 months after
implementation ends to ascertain whether they
continue providing services in their new facilities,
diffusing PPIUD services to other parts of the
country.
9. Sustainability: Percentage of new providers providing
PPIUD services in intervention facilities 12 months
after the end of implementation
New providers not originally trained under the PPIUD
intervention, but who are working in intervention facilities
will be interviewed 12 months after the end of interven-
tion implementation to assess the diffusion of PPIUD
services to other providers within the facility.
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The study timeline and associated quantitative data
collection activities for each of the two groups of hospi-
tals are depicted in Fig. 1 for Tanzania and Fig. 2 for
Nepal and Sri Lanka.
Sample size
Following the cluster-randomized stepped-wedge design,
power calculations were performed on a per country
basis, assuming that 300 women are enrolled per hos-
pital per month over a 12-month study enrolment
period in Tanzania and an 18-month study enrolment
period in Nepal and Sri Lanka, and followed for up to
18 months postpartum to ascertain study endpoints [13].
It is expected that the study will enrol 21,600 women in
Tanzania and 32,400 women in Nepal and Sri Lanka.
1. PPIUD Counselling – Assuming that at the study
hospitals during the standard of care time periods,
the PPIUD counselling rate will be 1% or lower, we
will have 80% power or more to detect an increased
counselling rate of 2% or greater, even with an ICC
of 15% [14] or lower, assuming that at least 21,600
women are enrolled during the 12-18-month enrol-
ment period.
2. PPIUD Uptake – Assuming that at the study hospitals
during the standard of care time periods, the PPIUD
Fig. 1 SPIRIT Flow Diagram for Tanzania: PPIUD study quantitative data collection by hospital group
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uptake rate will be 1% or lower, we will have 80%
power or more to detect an increased PPIUD uptake
rate of 8% or higher, even with an ICC of 15% or lower.
3. PPIUD Expulsion Rate at 6 weeks – Assuming that
the PPIUD uptake rate increased to 8% during the
intervention periods at the study hospitals, there will
be 80% power or greater if the PPIUD expulsion rate
is assumed to be 20% before the intervention [15]
and drops to 5% or less after the intervention, for an
ICC of 5% or less, even with 20% loss to follow-up
postpartum or less. These analyses apply only to the
intervention periods at the six hospitals, and are
based upon a one-sample test for clustered data.
4. Modern contraceptive use at 6 weeks and 18
months – Assuming that modern contraceptive use
at 6 weeks will be 55% in Sri Lanka [16] and that it
will increase to 62% due to the availability of PPIUD
during the intervention periods, there will be 80%
power or more to detect this difference or anything
greater, even if 20% of the participants enrolled
during the antenatal period are lost to follow-up by
the six week postpartum milestone and if the ICC is
15% or less. In Tanzania and Nepal, power is greater
due to significantly lower modern contraceptive use
at 6 weeks in the control group. Scenarios are
similar for modern contraceptive use at 18 months.
Fig. 2 SPIRIT Flow Diagram for Nepal and Sri Lanka: PPIUD study quantitative data collection by hospital group
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5. Proportion pregnant within 18 months of index
pregnancy – Assuming that 24% of women who enrol
during the control periods are pregnant again within
18 months [17], there will be 80% power or more to
detect a decreased proportion pregnant by 18 months
of 19.4% or less, even if 20% of the clients enrolled
during the antenatal period are lost to follow-up by 18
months and if the ICC is 15% or less.
Thus, we conservatively expect excellent power within
each of the 3 countries for all primary endpoints of this
study, assuming 21,600 in Tanzania and 32,400 women in
Nepal and Sri Lanka are enrolled across the study hospitals
at a rate of 300/month. If between-country heterogeneity
analysis indicates that the effect sizes between the countries
appear to be comparable, we will pool the results across the
three countries for substantially greater power.
Data collection procedures
Quantitative
All quantitative data will be collected by trained inter-
viewers using an electronic Computer-Assisted Personal
Interview (CAPI) format using the Dimagi CommCare sur-
vey management system on Android-based tablets. At base-
line, women will be approached by study interviewers in
postnatal wards and asked if they are interested in learning
about the study. Women who are interested in learning
more are provided with an informed consent form (Add-
itional file 2) that is read aloud by the study interviewer.
Women who consent to participate will sign or provide a
thumbprint. The signature is captured electronically on the
tablet, but women will be given the option to sign the paper
copy if they prefer not to sign electronically. Tablets are
used to take a photo of paper copies of signatures or
thumbprints so that provision of consent is fully electronic.
Baseline interviews collect information on the extent of
counseling the woman received and to assess the primary
outcome, PPIUD uptake. At the time of the baseline
interview, women will be asked to provide their contact
information, including their phone numbers as well as
those of friends and family and directions to their homes to
facilitate contact for follow-up interviews.
At the end of the baseline interview, women who have
accepted PPIUD will be asked to return to the facility
for a PPIUD check-up 4–6 weeks after delivery. Data
collectors will complete the 4-6 week survey when par-
ticipants return to the health facility for this check-up.
The 9-month and 18-month surveys are based on the
Demographic and Health Surveys (DHS) questionnaire
format and will be conducted when women return to
the health facility for their child’s vaccinations. Women
who do not return to the health facility as scheduled will
be called and asked to come to the facility for their
interview. Women’s travel costs to the health facility will
be reimbursed by the study. In the event that women are
unable to return, interviewers may attempt to interview
them at their homes or another convenient location.
Data quality will be ensured through phone re-
interviews of approximately 5% of study participants,
conducted by the interview supervisor.
Providers selected for the baseline survey will be inter-
viewed using the CommCare survey management system 6
months after the intervention begins, and 12 months after
the intervention ends by trained interviewers. In the follow-
up surveys, all providers who completed the baseline inter-
view will be selected, including those who have left the fa-
cility, in order to capture the extent to which diffusion has
occurred. At 12 months after the end of the intervention,
new staff at the study hospitals, who arrived after the inter-
vention period was completed, will also be sampled to
evaluate the extent to which PPIUD has been institutional-
ized. Extensive follow-up information is collected on each
provider’s contact information as well as information of a
friend or family member to aid in retention.
Qualitative
Quantitative findings will be contextualized by qualitative
in-depth interviews (IDIs) with providers and women to
evaluate performance of the intervention. Twelve IDIs will
be conducted with providers after they have received
training through the FIGO intervention to understand
their experiences with the training and facilitators as well
as barriers to intervention implementation in their hos-
pital. Two providers will be recruited from each hospital
and purposively selected to represent different cadres of
provider, where multiple cadres are trained, or by pro-
vider’s sex. Twenty-four IDIs will be conducted with
women who have had at least two antenatal care visits fol-
lowing the start of the intervention to explore women’s
experiences with postpartum contraceptive counselling
during antenatal care and decision-making regarding post-
partum contraceptive use. Four women will be purposively
selected from each hospital based on socio -demographic
characteristics. Finally, IDIs will be conducted with an
additional 36 women who received a PPIUD after inter-
vention implementation. These IDIs will be conducted at
least nine months postpartum to understand women’s ex-
periences using the PPIUD. Six women will be purposively
selected from each hospital based on whether they have
continued or discontinued PPIUD over the postpartum
period. Interviews will be audio-recorded with partici-
pants’ permission, transcribed verbatim in the local lan-
guage, and translated to English.
Data management and monitoring
Data will be securely transferred from the Android tablets
onto a CommCare-supported secure cloud server at the
end of each working day. The CommCare cloud server is
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HIPAA-compliant and meets all the necessary security re-
quirements for storing Level 4 identifiable data as defined
by Harvard University. Once the data have been securely
transferred to the cloud server, the survey record on the
Android tablet is immediately erased. All data uploaded to
the CommCare cloud server is encrypted and password-
protected in accordance to the Level 4 data security and
storage regulations. For each collected data case, which will
consist of a participant data record, all personal identifiable
data will be separated from the other non-identifiable data.
The de-identified data will then be uploaded to an
encrypted password-protected FTP site on a daily or weekly
basis and will be circulated to the project investigators for
analysis purposes for the duration of the study. Internal
consistency checks and data validation are built into the
CommCare software, but de-identified data are also cleaned
monthly to promote data quality. Identifiable data will be
stored separately from the de-identified data on the Comm-
Care secure encrypted server for the duration of the study.
Identifiable data will only be accessed by in-country collab-
orators for the purpose of revisiting participants at the ap-
propriate follow-up periods.
Each country will have an independent Data and Safety
Monitoring Board (DSMB) to be comprised of three to five
members with at least: one epidemiologist or biostatistician,
one reproductive health expert, preferably an obstetrician/
gynaecologist (OB/GYN), and one social scientist or ethi-
cist. Each DSMB will meet every four months to review
interim results and monitor compliance with the study
protocol and review any adverse events associated with the
intervention, such as higher than expected expulsion or
complication rates. Additional information can be found in
the Terms of Reference for the PPIUD study DSMBs, which
is available upon request.
Study enumerators are responsible for filling out a
Protocol Deviation/Adverse Event Report. Reports will
be submitted to the interview supervisors, and reviewed
by the national study coordinator and the principal in-




To assess the causal effect of the intervention on the
antenatal counselling for PPIUD uptake, successful
PPIUD insertion, and continued use of PPIUD 9 and 18
months following delivery, individual-level conditional
logistic regression models will be used, stratifying on
hospital, and controlling for calendar time to remove
bias due to secular changes in outcomes unrelated to the
intervention, with the causal effect estimated by a binary
indicator of the status (standard of care or intervention)
of each woman’s hospital at the time of her delivery.
Semi-non-parametric methods to model secular trends
will be used to control for confounding by secular trends
as finely as needed [18].
Due to the randomized stepped-wedge design, results
will be reported adjusted only for hospital and calendar
time, alongside full multivariable adjusted results, in
which all measured known or potential determinants of
these outcomes are controlled for. Risk differences and
risk ratios will be reported, as transformations of the
odds ratios to be estimated by the conditional logistic re-
gression model. Causal inference will be strongest when
analysis is restricted to the subset of women enrolled
during months 4-9 of the project, although power will
likely be insufficient to detect effects of realistic sizes.
Selective loss to follow-up could be a concern for valid
estimation of the causal effect of the intervention on
PPIUD utilization 9 and 18-months post-delivery of the
index pregnancy, but active follow-up with home visits
will minimize this potential bias. Also, to account for this,
marginal structural models for dependent censoring will
be applied [19, 20], weighting individual observations by
the inverse of their probability not to be lost to follow-up,
as a richly parameterized function of all measured poten-
tial determinants of the relevant outcome. Attrition ana-
lysis would examine whether the characteristics of women
lost to follow-up are different than those completing
follow-up interviews. Effect modification by country and
other key features will be explored by assessing the signifi-
cance of any differences observed through likelihood ratio
tests in which the relevant cross-product term is in and
out of the model and by reporting stratum-specific point
and interval causal effect estimates for any statistically
significant differences. Should no effect modification by
country be evident, we shall aggregate the data from the
three countries and produce a single summary effect esti-
mate as above. Standard meta-analysis techniques will be
used to assess between country differences, including the
Q-test [21], I2 [22] and CVB [23]. The study is not de-
signed or powered to estimate differential effects by sub-
groups of providers, facilities, or women, and such
analyses will be undertaken with the caveat that it is sug-
gestive rather than causal.
In additional secondary analysis, at the hospital level,
we will employ a regression discontinuity approach by
comparing women who deliver in the hospital immedi-
ately prior to the intervention with women who deliver
immediately post intervention to obtain an estimate of
the causal effects of the intervention on the outcomes of
interest in each hospital.
The analysis of the provider and facility surveys will be
undertaken to estimate the extent of institutionalization
and diffusion. We will estimate to what extent providers
continue providing the service when they move to other
institutions. We will examine these effects for staff at
different levels of the provider workforce.
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Nested mixed-methods performance evaluation
The qualitative analyses that are part of this study will
be closely integrated in the design, implementation and
analytical stages of the quantitative component. Qualita-
tive and quantitative data collection will be carried out
synchronously. Analyses of the quantitative and qualita-
tive data will initially be conducted separately, and then
integrated later through iterative comparison of results
and their relationships using a mixed methods approach.
Dissemination
Trial results will be published in peer-reviewed journals,
and presented at national and international meetings and
conferences. Authorship will be determined by a publica-
tions committee, which includes members from all organi-
zations involved in the study. Briefs indicating policy and
programmatic implications of findings will be produced,
and sessions will be organized involving national OB/GYN
societies and government officials in discussions on trans-
lating evidence into action. Results are expected to guide
the development of interventions to meet women’s need
for unintended pregnancy prevention and enable policy
makers and other stakeholders to make informed decisions
in supporting programs and policies. The evidence gener-
ated by the study will also contribute to developing or up-
dating guidelines for postpartum contraception.
Availability of data and materials
To allow for utilization of study data for additional re-
search, the de-identified dataset will be made publicly
available following publication of trial results.
Roles and responsibilities
The faculty leaders of the project undertake essential
supervision activities. The key responsibilities of the des-
ignated full-time project principal investigator and fac-
ulty co-principal investigator include:
 Working with FIGO to mesh the research and
evaluation with the intervention
 Undertaking visits to the three countries to provide
technical advice and guidance
 Working with the National Societies of
Obstetricians and Gynaecologists in each of the
three countries
 Ensuring the quality of the survey and qualitative
work in each country
 Reviewing adequate enrolment of study participants
according to the project timeline
 Providing technical advice and supporting the work
of other project team members
 Leading interim and final analysis of the data generated
 Disseminating information and lessons learned on
postpartum contraception and PPIUD in particular
during international, regional and national scientific
conferences/meetings.
Other Harvard T.H. Chan School of Public Health fac-
ulty serve as co-investigators. The principal investigators
and supervising faculty are supported by a postdoctoral
research fellow, three half-time research assistants and a
project manager.
At the national level, a full time country coordinator,
employed by the field implementing partner institution,
will assume overall responsibility for project activities,
including its local financial management. The core func-
tions of the National Coordinator will include:
 Organizing training activities and supervision of
national project staff
 Putting in place the required data collection systems
 Ensuring that the quality of the data collected is
maintained at a high level
 Reviewing the performance of the research staff at
each participating hospital
Discussion
The provision of PPIUD is critical for meeting women’s
need for long-term but reversible contraceptive protection.
This cluster-randomized stepped-wedge trial will assess the
causal effect of FIGO’s intervention to increase PPIUD
uptake and continuation, as well as to institutionalize and
diffuse these services after intervention implementation
ends, providing essential information for program imple-
menters and policy makers. This is the first study of its kind
with potential to yield results both on the effectiveness of
the intervention to enable women to space their births, and
on the effectiveness of the intervention approach to create
sustainable access to PPIUD services.
Additional files
Additional file 1: WHO Trial Registration Data. Information required by
the World Health Organization on trial registration. (DOCX 16 kb)
Additional file 2: Example recruitment scripts and informed consent
forms from Nepal. Recruitment script and informed consent form for
women and providers in Nepal. (DOCX 29 kb)
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